Sir -A recent study of cancer patients undergoing cytotoxic drug treatment has strongly implicated noradrenaline as a potentiator of the delayed nausea and vomiting response (Fredrikson et al., 1994) . Specific receptors for noradrenaline would appear to be involved since a correlation between post-chemotherapy nausea and levels of noradrenaline, but not adrenaline, was observed. It is worth noting that these findings, and those reported previously showing that catecholamines can up-regulate nausea and vomiting (Andrews et al., 1988; Leslie and Reynolds, 1993) , could have important implications in another approach to cancer treatment.
Targeted radiotherapy using meta-["'Oiodobenzylguanidine (MIBG) is a promising treatment for neuroblastoma and other neuroendocrine tumours. This radiopharmaceutical is accumulated in tumour via the noradrenaline transporter.
Since a therapeutic dose of ['31I]MIBG (7.4-14.8 GBq) contains 7-14 mg of this biogenic amine, the relationship between noradrenaline and nausea observed by Fredrikson et al. (1994) might unfortunately be relevant. Indeed, the administration of therapeutic doses of MIBG has been associated with nausea (Shapiro and Fischer, 1985) .
Currently, a UKCCSG-coordinated study is [1311]MIBG preparation could be a more effective agent than the conventional preparation (Mairs et al., 1994) . The n.c.a. preparation is both more toxic to neuroblastoma cells in culture and exhibits greater uptake in human neuroblastoma xenografts than the iodine exchange preparation.
We are currently investigating whether such advantages will also exist in patients. However, even if tumour targeting of n.c.a. MIBG was the same as that of the standard preparation, we believe that the potential lack of side-effects with n.c.a. ['31I]MIBG is sufficient rationale for the use of this radiopharmaceutical. We hope that the radiopharmaceutical industry will consider producing n.c.a. ['31I]MIBG despite the relatively small numbers of patients treated with this agent.
